TW201613563A - Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof - Google Patents
Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereofInfo
- Publication number
- TW201613563A TW201613563A TW104118984A TW104118984A TW201613563A TW 201613563 A TW201613563 A TW 201613563A TW 104118984 A TW104118984 A TW 104118984A TW 104118984 A TW104118984 A TW 104118984A TW 201613563 A TW201613563 A TW 201613563A
- Authority
- TW
- Taiwan
- Prior art keywords
- capecitabine
- cyclophosphamide
- layer tablet
- tablet formulations
- metronomic administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1596DE2014 | 2014-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201613563A true TW201613563A (en) | 2016-04-16 |
Family
ID=53724388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104118984A TW201613563A (en) | 2014-06-12 | 2015-06-11 | Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR100820A1 (fr) |
| TW (1) | TW201613563A (fr) |
| WO (1) | WO2015189807A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018013428A (es) * | 2016-05-03 | 2019-10-07 | Intas Pharmaceuticals Ltd | Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| US20140309183A1 (en) * | 2011-08-24 | 2014-10-16 | David Kerr | Low-Dose Combination Chemotherapy |
| CA2925960A1 (fr) * | 2013-09-30 | 2015-04-02 | Intas Pharmaceuticals Limited | Composition pharmaceutique comprenant de la capecitabine et du cyclophosphamide |
-
2015
- 2015-06-11 AR ARP150101871A patent/AR100820A1/es unknown
- 2015-06-11 TW TW104118984A patent/TW201613563A/zh unknown
- 2015-06-12 WO PCT/IB2015/054447 patent/WO2015189807A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AR100820A1 (es) | 2016-11-02 |
| WO2015189807A1 (fr) | 2015-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004557B (en) | Modulatory polynucleotides | |
| ZA202202711B (en) | Sustained-release dosage forms of ruxolitinib | |
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| EP4620519A3 (fr) | Procédés et compositions se rapportant à des chondroïsomes provenant de produits sanguins | |
| TW201613901A (en) | New compounds | |
| MX378435B (es) | Administración específica del sitio de un inhibidor de btk. | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| IN2014MU00303A (fr) | ||
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
| EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| IN2013MU03118A (fr) | ||
| TW201613563A (en) | Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof | |
| MX2018005134A (es) | Formulacion de factor viii (fviii). | |
| NZ739679A (en) | Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |